MedTrace Logo

Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi

NCT01213576 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2015-02-27

Study results available
· View outcomes & findings →

Summary

Albendazole and ivermectin are currently used in combination for annual mass treatment of lymphatic filariasis in Africa. Although the drugs have been donated, the cost of such programmes is very high and has proven to be a major impediment to the success of programmes in many countries with limited financial resources.

Data from albendazole treatment of other filarial infections and one study comparing single to multi-dose Diethycarbamazine/albendazole in lymphatic filariasis suggest that increased dose and/or frequency of albendazole dosing may be more effective in clearing microfilariae. It is essential to determine whether such higher doses are indeed beneficial since this could have far-reaching effects on the conduct and management of the main mass treatment programmes and also in the management of programmes as they near elimination.

Conditions

  • Lymphatic Filariasis

Interventions

DRUG

Albendazole 400mg and ivermectin 200mcg/kg

400 mg orally given annually

DRUG

Albendazole and ivermectin

albendazole 800 mg and ivermectin 400mg orally given annually

DRUG

Albendazole 400mg and ivermectin 200mcg/kg

Albendazole 400mg and ivermectin 200mcg/kg given twice a year

DRUG

albendazole 800mg and ivermectin 400mcg/kg bi-annually

albendazole 800mg and ivermectin 400mcg/kg given twice a year

Sponsors & Collaborators

  • Emory University

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Neil French, MB ChB PHD · London School of Hygiene and Tropical Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Malawi

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213576 on ClinicalTrials.gov